Report copyright - Efficacy Claims and Subset Analyses in Phase III: Some ... · IPASS: Phase III study of IRESSA versus doublet chemotherapy in first line NSCLC IRESSA 250 mg/day. Carboplatin AUC 5
Please pass captcha verification before submit form